Company Of The Day: Pfizer

July 9th, 2021 by Trefis Team
+40.07%
Upside
25.86
Market
36.22
Trefis
PFE: Pfizer logo
PFE
Pfizer

What? 

Pfizer (NYSE:PFE) and its German partner BioNTech intend to begin clinical trials for an updated version of their Covid-19 vaccine that targets the Delta variant of the Coronavirus.

Why?

Relevant Articles
  1. What’s Next For Pfizer Stock?
  2. What’s Behind The 50% Fall In Pfizer Stock?
  3. What Trends Will Drive Pfizer’s Q3?
  4. Will Pfizer Stock See Higher Levels?
  5. 2x Returns Possible For Pfizer Stock?
  6. Is Pfizer Stock A Better Pick Over AbbVie?

The Delta variant apparently more transmissible compared to other strains of the virus. There are also concerns about the efficacy of the current generation of Covid-19 vaccines against the variant.

So What?

Pfizer and BioNtech are already generating windfall profits from their Covid-19 shot. Pfizer projects vaccine sales of $26 billion for this year – a conservative figure, in our view. With shots targeting new virus variants, the companies could keep their Covid vaccine sales going for a few more years.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016

See all Trefis Price Estimates and Download Trefis Data here

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams